{"id":800476,"date":"2025-01-14T08:11:54","date_gmt":"2025-01-14T13:11:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/"},"modified":"2025-01-14T08:11:54","modified_gmt":"2025-01-14T13:11:54","slug":"annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/","title":{"rendered":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection"},"content":{"rendered":"
\n

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. <\/p>\n

This newly issued patent is based on buntanetap\u2019s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now holds global protection for the use of buntanetap in treating acute neurodegenerative disorders. <\/p>\n

\u201cNerve cells are inherently delicate and susceptible to structural damage upon physical impact. Buntanetap works by targeting the neurotoxic pathways that contribute to this damage, providing a potential path to protect and restore neuronal health,\u201d commented Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. \u201cWe are proud to add this patent to our growing intellectual property portfolio, further expanding the possible applications of buntanetap beyond its primary indications such as Alzheimer\u2019s and Parkinson\u2019s diseases.\u201d<\/p>\n

The U.S. Patent and Trademark Office (USPTO) issued the patent on January 2, 2025, under the publication number US-2025-0000846-A1.<\/p>\n

\n About Annovis Bio<\/b>\n <\/p>\n

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company\u2019s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com<\/a> and follow us on LinkedIn, YouTube, and X.<\/p>\n

\n Investor Alerts<\/b>\n <\/p>\n

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https:\/\/www.annovisbio.com\/email-alerts<\/a>. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company’s plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company’s clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company’s periodic filings with the SEC, including those listed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n

\n Contact Information<\/b>:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com<\/a><\/p>\n

\n Investor Contact:<\/b>
\n
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com\/investors-relations
IR@annovisbio.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap\u2019s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now … <\/p>\n

Continue reading “Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-800476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnnovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap\u2019s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now … Continue reading "Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T13:11:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection\",\"datePublished\":\"2025-01-14T13:11:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/\"},\"wordCount\":583,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/\",\"name\":\"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==\",\"datePublished\":\"2025-01-14T13:11:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk","og_description":"MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap\u2019s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now … Continue reading \"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-14T13:11:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection","datePublished":"2025-01-14T13:11:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/"},"wordCount":583,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/","name":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==","datePublished":"2025-01-14T13:11:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMTA2NCM2NjkxNDk2IzUwMDA3ODQ2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-securing-global-protection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=800476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=800476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=800476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=800476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}